Results 161 to 170 of about 1,569,733 (298)

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule   +12 more
wiley   +1 more source

Reverse transcriptase inhibitors enable the generation of fertile spermatids from fetal mouse testes in vitro. [PDF]

open access: yesCommun Biol
Nishida M   +11 more
europepmc   +1 more source

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras   +6 more
wiley   +1 more source

Inhibition of long interspersed nuclear element-1 by nucleoside reverse transcriptase inhibitors attenuates vascular calcification. [PDF]

open access: yesSignal Transduct Target Ther
Ma J   +13 more
europepmc   +1 more source

Natural Products as HIV Reverse Transcriptase Inhibitors

open access: yes, 2009
Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos.
Gonçalves, R. S. B.   +3 more
core  

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan   +6 more
wiley   +1 more source

Reverse transcriptase inhibitors in Aicardi-Goutières syndrome: A crossover clinical trial. [PDF]

open access: yesDev Med Child Neurol
Crow YJ   +8 more
europepmc   +1 more source

Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs. dolutegravir‐containing antiretroviral regimens

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
This study investigates intracellular (IC) exposure of tenofovir alafenamide (TAF) and its clinical determinants in experienced people living with HIV. We conducted a monocentric retrospective analysis of 86 adults treated with either bictegravir (BIC)‐ or dolutegravir (DTG)‐containing regimen. Plasma and IC trough concentrations (Ctrough) of tenofovir
Micol Ferrara   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy